772 related articles for article (PubMed ID: 22593575)
21. Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver.
Sun X; Essalmani R; Day R; Khatib AM; Seidah NG; Prat A
Neoplasia; 2012 Dec; 14(12):1122-31. PubMed ID: 23308045
[TBL] [Abstract][Full Text] [Related]
22. Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line.
Ruscica M; Ricci C; Macchi C; Magni P; Cristofani R; Liu J; Corsini A; Ferri N
J Biol Chem; 2016 Feb; 291(7):3508-19. PubMed ID: 26668321
[TBL] [Abstract][Full Text] [Related]
23. Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9.
Le QT; Blanchet M; Seidah NG; Labonté P
J Biol Chem; 2015 Sep; 290(38):23385-400. PubMed ID: 26195630
[TBL] [Abstract][Full Text] [Related]
24. Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation.
Tavori H; Fan D; Blakemore JL; Yancey PG; Ding L; Linton MF; Fazio S
Circulation; 2013 Jun; 127(24):2403-13. PubMed ID: 23690465
[TBL] [Abstract][Full Text] [Related]
25. Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels.
Lipari MT; Li W; Moran P; Kong-Beltran M; Sai T; Lai J; Lin SJ; Kolumam G; Zavala-Solorio J; Izrael-Tomasevic A; Arnott D; Wang J; Peterson AS; Kirchhofer D
J Biol Chem; 2012 Dec; 287(52):43482-91. PubMed ID: 23135270
[TBL] [Abstract][Full Text] [Related]
26. An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes.
Zhang L; McCabe T; Condra JH; Ni YG; Peterson LB; Wang W; Strack AM; Wang F; Pandit S; Hammond H; Wood D; Lewis D; Rosa R; Mendoza V; Cumiskey AM; Johns DG; Hansen BC; Shen X; Geoghagen N; Jensen K; Zhu L; Wietecha K; Wisniewski D; Huang L; Zhao JZ; Ernst R; Hampton R; Haytko P; Ansbro F; Chilewski S; Chin J; Mitnaul LJ; Pellacani A; Sparrow CP; An Z; Strohl W; Hubbard B; Plump AS; Blom D; Sitlani A
Int J Biol Sci; 2012; 8(3):310-27. PubMed ID: 22355267
[TBL] [Abstract][Full Text] [Related]
27. FoxO3 transcription factor and Sirt6 deacetylase regulate low density lipoprotein (LDL)-cholesterol homeostasis via control of the proprotein convertase subtilisin/kexin type 9 (Pcsk9) gene expression.
Tao R; Xiong X; DePinho RA; Deng CX; Dong XC
J Biol Chem; 2013 Oct; 288(41):29252-9. PubMed ID: 23974119
[TBL] [Abstract][Full Text] [Related]
28. Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor.
Lambert G; Jarnoux AL; Pineau T; Pape O; Chetiveaux M; Laboisse C; Krempf M; Costet P
Endocrinology; 2006 Oct; 147(10):4985-95. PubMed ID: 16794006
[TBL] [Abstract][Full Text] [Related]
29. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
[TBL] [Abstract][Full Text] [Related]
30. CETP inhibitors downregulate hepatic LDL receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent mechanism.
Dong B; Singh AB; Fung C; Kan K; Liu J
Atherosclerosis; 2014 Aug; 235(2):449-62. PubMed ID: 24950000
[TBL] [Abstract][Full Text] [Related]
31. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment.
Maxwell KN; Fisher EA; Breslow JL
Proc Natl Acad Sci U S A; 2005 Feb; 102(6):2069-74. PubMed ID: 15677715
[TBL] [Abstract][Full Text] [Related]
32. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels.
Ferri N; Tibolla G; Pirillo A; Cipollone F; Mezzetti A; Pacia S; Corsini A; Catapano AL
Atherosclerosis; 2012 Feb; 220(2):381-6. PubMed ID: 22176652
[TBL] [Abstract][Full Text] [Related]
33. Identification of neolignans with PCSK9 downregulatory and LDLR upregulatory activities from Penthorum chinense and the potential in cholesterol uptake by transcriptional regulation of LDLR via SREBP2.
Chae HS; Pel P; Cho J; Kim YM; An CY; Huh J; Choi YH; Kim J; Chin YW
J Ethnopharmacol; 2021 Oct; 278():114265. PubMed ID: 34111537
[TBL] [Abstract][Full Text] [Related]
34. Hepatitis C virus stimulates low-density lipoprotein receptor expression to facilitate viral propagation.
Syed GH; Tang H; Khan M; Hassanein T; Liu J; Siddiqui A
J Virol; 2014 Mar; 88(5):2519-29. PubMed ID: 24352472
[TBL] [Abstract][Full Text] [Related]
35. Delineation of molecular pathways that regulate hepatic PCSK9 and LDL receptor expression during fasting in normolipidemic hamsters.
Wu M; Dong B; Cao A; Li H; Liu J
Atherosclerosis; 2012 Oct; 224(2):401-10. PubMed ID: 22954675
[TBL] [Abstract][Full Text] [Related]
36. Endoplasmic Reticulum Stress and Ca2+ Depletion Differentially Modulate the Sterol Regulatory Protein PCSK9 to Control Lipid Metabolism.
Lebeau P; Al-Hashimi A; Sood S; Lhoták Š; Yu P; Gyulay G; Paré G; Chen SR; Trigatti B; Prat A; Seidah NG; Austin RC
J Biol Chem; 2017 Jan; 292(4):1510-1523. PubMed ID: 27909053
[TBL] [Abstract][Full Text] [Related]
37. On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects.
Tavori H; Rashid S; Fazio S
Atherosclerosis; 2015 Feb; 238(2):264-70. PubMed ID: 25544176
[TBL] [Abstract][Full Text] [Related]
38. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2.
Poirier S; Mayer G; Benjannet S; Bergeron E; Marcinkiewicz J; Nassoury N; Mayer H; Nimpf J; Prat A; Seidah NG
J Biol Chem; 2008 Jan; 283(4):2363-72. PubMed ID: 18039658
[TBL] [Abstract][Full Text] [Related]
39. Schisandrin A in
Kim HJ; Park SK; Park SH; Lee YG; Park JH; Hwang JT; Chung MY
J Microbiol Biotechnol; 2024 Feb; 34(2):425-435. PubMed ID: 37997262
[No Abstract] [Full Text] [Related]
40. Reduced VLDL clearance in Apoe(-/-)Npc1(-/-) mice is associated with increased Pcsk9 and Idol expression and decreased hepatic LDL-receptor levels.
Ishibashi M; Masson D; Westerterp M; Wang N; Sayers S; Li R; Welch CL; Tall AR
J Lipid Res; 2010 Sep; 51(9):2655-63. PubMed ID: 20562239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
